High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study.

BACKGROUND The physiological role of lipoprotein(a) is unclear; however, lipoprotein(a) may play a role in hemostasis and wound healing. We tested the hypothesis that high lipoprotein(a) concentrations are associated with low risk of major bleeding in the brain and airways both observationally and causally (from human genetics). METHODS We examined 109169 individuals from the Copenhagen City Heart Study and the Copenhagen General Population study, 2 similar prospective studies conducted in the Danish general population. Individuals had information on plasma lipoprotein(a) concentrations (n = 59980), LPA kringle-IV type 2 (KIV-2) number of repeats (n = 98965), and/or LPA single-nucleotide polymorphism rs10455872 associated with high lipoprotein(a) concentrations (n = 109 169), and information on hospital contacts or death due to major bleeding in brain and airways from registers. RESULTS Using extreme phenotypes or genotypes, the multifactorially adjusted hazard ratio for major bleeding in the brain and airways was 0.84 (95%CI: 0.71-0.99) for lipoprotein(a), >800 mg/L vs <110 mg/L; 0.83 (0.73-0.96) for KIV-2, <24 vs >35 number of repeats; and 0.89 (0.81-0.97) for rs10455872 carriers (heterozygotes + homozygotes) vs noncarriers. The corresponding hazard ratios were 0.89 (0.82-0.98) for heterozygotes and 0.59 (0.36-0.98) for homozygotes separately vs rs10455872 noncarriers. Also, for a 1 standard deviation higher lipoprotein(a) (= 310 mg/L), the hazard ratio for major bleeding in the brain and airways was 0.95 (95%CI: 0.91-1.00) observationally, 0.89 (0.80-0.98) causally based on LPA KIV-2 number of repeats, and 0.94 (0.87-1.02) causally based on LPA rs10455872. CONCLUSIONS High lipoprotein(a) concentrations were associated with lower risk of major bleeding in the brain and airways observationally and causally. This indicates that lipoprotein(a) may play a role in hemostasis and wound healing.

[1]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[2]  F. Kronenberg,et al.  Structure, function, and genetics of lipoprotein (a) , 2016, Journal of Lipid Research.

[3]  J. Witztum,et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.

[4]  B. Nordestgaard,et al.  How Does Elevated Lipoprotein(a) Cause Aortic Valve Stenosis? , 2015, Journal of the American College of Cardiology.

[5]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  M. Boffa,et al.  Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)[S] , 2014, Journal of Lipid Research.

[7]  M. Sandhu,et al.  Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .

[8]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[9]  B. Nordestgaard,et al.  Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. , 2013, The lancet. Diabetes & endocrinology.

[10]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[11]  K. Kario,et al.  Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. , 2013, Thrombosis research.

[12]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[13]  K. Porter,et al.  Lipoprotein(a): Cellular Effects and Molecular Mechanisms , 2012, Cholesterol.

[14]  Anne Tybjærg-Hansen,et al.  Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Michael J.A. Williams,et al.  Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. , 2011, Journal of proteomics.

[16]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[17]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[18]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[19]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[20]  B. Nordestgaard,et al.  Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. , 2008, Circulation.

[21]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[22]  A. Szczeklik,et al.  Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis , 2006, Journal of thrombosis and haemostasis : JTH.

[23]  F. Castellino,et al.  Plasminogen receptors: the sine qua non of cell surface plasminogen activation. , 2005, Frontiers in bioscience : a journal and virtual library.

[24]  M. Boffa,et al.  Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. , 2004, Clinical biochemistry.

[25]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[26]  C. Kang,et al.  Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner: A Study With Different-Length Recombinant Apo(a), Native Lp(a), and Monoclonal Antibody , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[27]  R. Simari,et al.  Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. , 2001, Blood.

[28]  E. Madison,et al.  The Kringle V-Protease Domain Is a Fibrinogen Binding Region within Apo(a) , 2001, Thrombosis and Haemostasis.

[29]  E. Angles-cano,et al.  Inhibition of Fibrinolysis by Lipoprotein(a) , 2001, Annals of the New York Academy of Sciences.

[30]  M. Koschinsky,et al.  Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). , 1995, Biochemistry.

[31]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[32]  J. Goldstein,et al.  Teaching old dogmas new tricks , 1987, Nature.

[33]  M. Brown,et al.  Plasma lipoproteins: teaching old dogmas new tricks. , 1987, Nature.

[34]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.